文献リスト

1）Yuki N, Taki T, Inagaki F, et al. A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure. J Exp Med. 1993; 178: 1771-5

2）Yuki N. Ganglioside mimicry and peripheral nerve disease. Muscle Nerve. 2007; 35: 691-711

3）Chiba A, Kusunoki S, Obata H, et al. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology. 1993; 43: 1911-7

4）Koga M, Gilbert M, Li J, et al. Antecedent infections in Fisher syndrome: a common pathogenesis of molecular mimicry. Neurology. 2005; 64: 1605-11

5）Shin JE, Ackloo S, Mainkar AS, et al. Lipo-oligosaccharides of Campylobacter jejuni serotype O: 10. Structures of core oligosaccharide regions from a bacterial isolate from a patient with the Miller-Fisher syndrome and from the serotype reference strain. Carbohydr Res. 1997; 305: 223-32

6）Houliston RS, Koga M, Li J, et al. A Haemophilus influenzae strain associated with Fisher syndrome expresses a novel disialylated ganglioside mimic. Biochemistry. 2007; 46: 8164-71

7）Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain. 2002; 125: 2591-625

8）Lardone RD, Yuki N, Odaka M, et al. Anti-GM1 IgG antibodies in Guillain-Barré syndrome: fine specificity is associated with disease severity. J Neurol Neurosurg Psychiatry. 2010; 81: 629-33

9）Lopez PH, Zhang G, Bianchet MA, et al. Structural requirements of anti-GD1a antibodies determine their target specificity. Brain. 2008; 131: 1926-39

10）Kaida K, Kusunoki S, Kamakura K, et al. GalNAc-GD1a in human peripheral nerve: target sites of anti-ganglioside antibody. Neurology. 2003; 61: 465-70

11）Yuki N, Ang CW, Koga M, et al. Clinical features and response to treatment in Guillain-Barré syndrome associated with antibodies to GM1b ganglioside. Ann Neurol. 2000; 47: 314-21

12）Ito M, Kuwabara S, Odaka M, et al. Bickerstaffʼs brainstem encephalitis and Fisher syndrome form a continuous spectrum: clinical analysis of 581 cases. J Neurol. 2008; 255: 674-82

13）Wakerley BR, Uncini A, Yuki N, the GBS Classification Group. Guillain-Barré and Miller Fisher syndromes--new diagnostic classification. Nat Rev Neurol. 2014; 10: 537-44

14）Ito M, Matsuno K, Sakumoto Y, et al. Ataxic Guillain-Barré syndrome and acute sensory ataxic neuropathy form a continuous spectrum. J Neurol Neurosurg Psychiatry. 2011; 82: 294-9

15）Kusunoki S, Shimizu J, Chiba A, et al. Experimental sensory neuropathy induced by sensitization with ganglioside GD1b. Ann Neurol. 1996; 39: 424-31

16）Susuki K, Yuki N, Schafer DP, et al. Dysfunction of nodes of Ranvier: a mechanism for anti-ganglioside antibody-mediated neuropathies. Experimental neurology. 2012; 233: 534-42

17）Nagashima T, Koga M, Odaka M, et al. Clinical correlates of serum anti-GT1a IgG antibodies. J Neurol Sci. 2004; 219: 139-45

18）Ilyas AA, Chou DK, Jungalwala FB, et al. Variability in the structural requirements for binding of human monoclonal anti-myelin-associated glycoprotein immunoglobulin M antibodies and HNK-1 to sphingoglycolipid antigens. J Neurochem. 1990; 55: 594-601

19）Kaida K, Morita D, Kanzaki M, et al. Ganglioside complexes as new target antigens in Guillain-Barré syndrome. Ann Neurol. 2004; 56: 567-71

20）Kaida K, Morita D, Kanzaki M, et al. Anti-ganglioside complex antibodies associated with severe disability in GBS. J Neuroimmunol. 2007; 182: 212-8

21）Shahrizaila N, Kokubun N, Sawai S, et al. Antibodies to single glycolipids and glycolipid complexes in Guillain-Barré syndrome subtypes. Neurology. 2014; 83: 118-24

22）Kaida K, Kanzaki M, Morita D, et al. Anti-ganglioside complex antibodies in Miller Fisher syndrome. J Neurol Neurosurg Psychiatry. 2006; 77: 1043-6

23）Koga M, Gilbert M, Takahashi M, et al. GQ1b-seronegative Fisher syndrome: clinical features and new serological markers. J Neurol. 2012; 259: 1366-74

24）Kaida K, Sonoo M, Ogawa G, et al. GM1/GalNAc-GD1a complex: a target for pure motor Guillain-Barré syndrome. Neurology. 2008; 71: 1683-90

25）Creange A, Shahrizaila N, Salhi H, et al. Association of antibodies to ganglioside complexes and conduction blocks in axonal Guillain-Barré syndrome presenting as acute motor conduction block neuropathy. J Peripher Nerv Syst. 2014; 19: 115-20

26）Yuki N, Fukami Y, Yanaka C, et al. GD1b-specific antibodies may bind to complex of GQ1b and GM1, causing ataxia. J Neurol. 2014; 261: 1565-9

27）Zweiman B, Rostami A, Lisak RP, et al. Immune reactions to P2 protein in human inflammatory demyelinative neuropathies. Neurology. 1983; 33: 234-7

28）Khalili-Shirazi A, Atkinson P, Gregson N, et al. Antibody responses to P0 and P2 myelin proteins in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy. J Neuroimmunol. 1993; 46: 245-51

29）Yan WX, Archelos JJ, Hartung HP, et al. P0 protein is a target antigen in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 2001; 50: 286-92

30）Kwa MS, van Schaik IN, Brand A, et al. Investigation of serum response to PMP22, connexin 32 and P(0)in inflammatory neuropathies. J Neuroimmunol. 2001; 116: 220-5

31）Miki Y, Tomiyama M, Haga R, et al. A family with IVIg-responsive Charcot-Marie-Tooth disease. J Neurol. 2013; 260: 1147-51

32）Gabriel CM, Gregson NA, Hughes RA. Anti-PMP22 antibodies in patients with inflammatory neuropathy. J Neuroimmunol. 2000; 104: 139-46

33）Lim JP, Devaux J, Yuki N. Peripheral nerve proteins as potential autoantigens in acute and chronic inflammatory demyelinating polyneuropathies. Autoimmun Rev. 2014; 13: 1070-8

34）Ritz MF, Lechner-Scott J, Scott RJ, et al. Characterisation of autoantibodies to peripheral myelin protein 22 in patients with hereditary and acquired neuropathies. J Neuroimmunol. 2000; 104: 155-63

35）Inglis HR, Csurhes PA, McCombe PA. Antibody responses to peptides of peripheral nerve myelin proteins P0 and P2 in patients with inflammatory demyelinating neuropathy. J Neurol Neurosurg Psychiatry. 2007; 78: 419-22

36）Makowska A, Pritchard J, Sanvito L, et al. Immune responses to myelin proteins in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry. 2008; 79: 664-71

37）Hughes RA, Gray IA, Gregson NA, et al. Immune responses to myelin antigens in Guillain-Barré syndrome. J Neuroimmunol. 1984; 6: 303-12

38）Lawlor MW, Richards MP, De Vries GH, et al. Antibodies to L-periaxin in sera of patients with peripheral neuropathy produce experimental sensory nerve conduction deficits. J Neurochem. 2002; 83: 592-600

39）Nevo Y, Ben-Zeev B, Tabib A, et al. CD59 deficiency is associated with chronic hemolysis and childhood relapsing immune-mediated polyneuropathy. Blood. 2013; 121: 129-35

40）Pintér C, Beltrami S, Caputo D, et al. Presence of autoantibodies against complement regulatory proteins in relapsing-remitting multiple sclerosis. J Neurovirol. 2000; 6 Suppl 2: S42-6

41）Miyaji K, Shahrizaila N, Umapathi T, et al. Complement regulatory proteins (CD46, 55 and 59) expressed on Schwann cells: Immune targets in demyelinating neuropathies? J Neuroimmunol. 2014. Epub ahead of print

42）Sawai S, Satoh M, Mori M, et al. Moesin is a possible target molecule for cytomegalovirus-related Guillain-Barré syndrome. Neurology. 2014; 83: 113-7

43）Miyaji K, Shahrizaila N, Umapathi T, et al. Are ERM (ezrin/radixin/moesin) proteins targets for autoantibodies in demyelinating neuropathies? Hum Immunol. 2014. [Epub ahead of print]

44）Sherman DL, Tait S, Melrose S, et al. Neurofascins are required to establish axonal domains for saltatory conduction. Neuron. 2005; 48: 737-42

45）Mathey EK, Derfuss T, Storch MK, et al. Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med. 2007; 204: 2363-72

46）Pruss H, Schwab JM, Derst C, et al. Neurofascin as target of autoantibodies in Guillain-Barré syndrome. Brain. 2011; 134: e173; author reply e174

47）Devaux JJ, Odaka M, Yuki N. Nodal proteins are target antigens in Guillain-Barré syndrome. J Peripher Nerv Syst. 2012; 17: 62-71

48）Lonigro A, Devaux JJ. Disruption of neurofascin and gliomedin at nodes of Ranvier precedes demyelination in experimental allergic neuritis. Brain. 2009; 132: 260-73

49）Querol L, Nogales-Gadea G, Rojas-Garcia R, et al. Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. Neurology. 2014; 82: 879-86

50）Kawamura N, Yamasaki R, Yonekawa T, et al. Anti-neurofascin antibody in patients with combined central and peripheral demyelination. Neurology. 2013; 81: 714-22

51）Ng JK, Malotka J, Kawakami N, et al. Neurofascin as a target for autoantibodies in peripheral neuropathies. Neurology. 2012; 79: 2241-8

52）Devaux JJ. Antibodies to gliomedin cause peripheral demyelinating neuropathy and the dismantling of the nodes of Ranvier. Am J Pathol. 2012; 181: 1402-13

53）Boyle ME, Berglund EO, Murai KK, et al. Contactin orchestrates assembly of the septate-like junctions at the paranode in myelinated peripheral nerve. Neuron. 2001; 30: 385-97

54）Labasque M, Hivert B, Nogales-Gadea G, et al. Specific contactin N-glycans are implicated in neurofascin binding and autoimmune targeting in peripheral neuropathies. J Biol Chem. 2014; 289: 7907-18

55）Tuzun E, Kinay D, Hacohen Y, et al. Guillain-Barré-like syndrome associated with lung adenocarcinoma and CASPR2 antibodies. Muscle Nerve. 2013; 48: 836-7

56）Poliak S, Salomon D, Elhanany H, et al. Juxtaparanodal clustering of Shaker-like K＋ channels in myelinated axons depends on Caspr2 and TAG-1. J Cell Biol. 2003; 162: 1149-60

57）Iijima M, Tomita M, Morozumi S, et al. Single nucleotide polymorphism of TAG-1 influences IVIg responsiveness of Japanese patients with CIDP. Neurology. 2009; 73: 1348-52

58）Derfuss T, Parikh K, Velhin S, et al. Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals. Proc Natl Acad Sci U S A. 2009; 106: 8302-7

59）Querol L, Nogales-Gadea G, Rojas-Garcia R, et al. Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy. Ann Neurol. 2013; 73: 370-80

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp